Last reviewed · How we verify
Imprimis Dropless
Imprimis Dropless is a compounded ophthalmic formulation combining multiple anti-inflammatory and antimicrobial agents to prevent infection and inflammation following cataract surgery without requiring separate post-operative eye drops.
Imprimis Dropless is a compounded ophthalmic formulation combining multiple anti-inflammatory and antimicrobial agents to prevent infection and inflammation following cataract surgery without requiring separate post-operative eye drops. Used for Prevention of post-operative inflammation and infection following cataract surgery.
At a glance
| Generic name | Imprimis Dropless |
|---|---|
| Sponsor | Eye Center of North Florida |
| Drug class | Compounded ophthalmic anti-inflammatory and antimicrobial combination |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This is a customized, preservative-free compounded medication that integrates corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and antibiotics into a single formulation. It is injected into the eye during cataract surgery to provide sustained therapeutic levels throughout the post-operative period, eliminating the need for patients to instill multiple topical drops at home.
Approved indications
- Prevention of post-operative inflammation and infection following cataract surgery
Common side effects
- Corneal edema
- Elevated intraocular pressure
- Anterior chamber inflammation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imprimis Dropless CI brief — competitive landscape report
- Imprimis Dropless updates RSS · CI watch RSS
- Eye Center of North Florida portfolio CI